Aurobindo’s Sandoz deal may face further delays

In September, Hyderabad-based Aurobindo announced that it would acquire the commercial operations of Swiss drug maker Novartis AGs’ generics unit in the US for $900 million. However, the proposed deal, which could emerge as the largest outbound deal by an Indian company, is yet to see the light of day considering that the FTC is yet to respond.

from Moneycontrol Business News https://www.moneycontrol.com/news/business/aurobindo’s-sandoz-deal-may-face-further-delays_12818221.html